The University of Petra "جامعة البترا"​ in Jordan recently announced the formation of room temperature therapeutic deep eutectic solvent (THEDES) of Risperidone for the first time.

‍

‍

The antipsychotic drug that is used in the treatment of schizophrenia, manic states associated with bipolar disorder and irritability in children with autism, Risperidone is currently commercially available as a conventional tablet, dispersible tablet, oral liquid solution or intramuscular injection.

‍

The conversion of the active pharmaceutical agent (API) into liquid form using deep eutectic solvents (DES) to form THEDES has been reported to have many formulation advantages, including enhanced skin permeation for transdermal drugdelivery, which in turn may help improve its overall bioavailability, which is typically low.

‍

This is an exciting development and one which is likely to enable its use in Transdermal Drug Delivery!

‍

Such discoveries and their subsequent transformation into transdermal patches by specialists such as US-based Greene Street Pharmaceuticals, offer new hope for patients and add further credence to the strength and possibilities available when academia and industry work together.

‍

Learn more about transdermals at their uses by getting in touch with us today.